Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Enhancing brown adipose tissue through NAD+ precursors: a new approach to treat cardiometabolic disease

Descrizione del progetto

Cellule adipose reclutate per combattere le malattie cardiovascolari

Centinaia di anni fa, gli scienziati hanno scoperto il tessuto adiposo bruno (BAT, Brown Adipose Tissue) nelle marmotte. Da allora in poi, l’interesse per il BAT ha avuto un andamento altalenante. È stato riscontrato in altri mammiferi e persino nei neonati e nei bambini piccoli, e si è consolidato un ruolo metabolico per il BAT. Cariche di mitocondri, queste cellule adipose specializzate generano calore corporeo, senza necessità di brividi. La scoperta negli adulti di un decennio fa e un ruolo dimostrato nella sensibilità all’insulina hanno generato un rinnovato interesse per il BAT quale via terapeutica verso trattamenti per malattie cardiometaboliche potenzialmente fatali. Il progetto eBAT sta studiando un attivatore potenzialmente molto potente del BAT in linee cellulari e modelli animali e come integratore alimentare.

Obiettivo

Cardiometabolic disease comprises a group of disorders including obesity, hypertension, dyslipidaemia, hypercholesterolaemia and glucose intolerance. These are the underlying cause of the majority of cardiovascular diseases, which represent the leading cause of morbidity and mortality in the Western World. The discovery of active brown adipose tissue (BAT) in adult humans in 2009 has increased the interest on the role of this tissue in the development of these disorders, and in the potential of its metabolic activation for their treatment. It has been demonstrated that BAT activation can be achieved by means of supplementation with NAD+ precursors, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). However, very little is known about how these compounds exert their effect on BAT and what the metabolic effects of their administration to this tissue are. This project proposes the use of an undescribed NAD+ precursor to induce BAT activation. I have already proved that this new compound is a more powerful NAD+-booster than NMN and NR. Thus, I hypothesize that it will be able to enhance BAT function more pronouncedly. By testing the effects of the supplementation of different cell lines and mouse models with this new compound, I aim to elucidate the molecular mechanisms underlying its NAD+-enhancing potential and the physiological changes that BAT undertakes upon its administration. Moreover, its encapsulation in nanoparticles for its oral administration through the diet will also be tested. This will be of outstanding relevance for its possible pharmacological use. The development of the research aims proposed in this project will shed light on the use of NAD+ precursors to activate BAT function, with the long-term ambition of establishing whether the use of these compounds is a suitable approach for the protection from cardiometabolic disease through the preservation of BAT phenotype.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2018

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Contributo netto dell'UE
€ 175 572,48
Indirizzo
MEIBERGDREEF 15
1105AZ Amsterdam
Paesi Bassi
Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 175 572,48